Evidence map›Paper›PMID 17638888›Full record

ArticleCancer research2007

Genetic ablation of CCAAT/enhancer binding protein alpha in epidermis reveals its role in suppression of epithelial tumorigenesis.

Kari D Loomis, Songyun Zhu, Kyungsil Yoon, Peter F Johnson, Robert C Smart

Open access · bronzeAbstract read
In one paragraph

Article in Cancer research, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Epidermal barriers.Cold Spring Harbor perspectives in medicine · 2014
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Kari D LoomisCell Signaling and Cancer Group, Department of Environmental and Molecular Toxicology and Functional Genomics Program, North Carolina State University, Raleigh, NC 27695, USA.
Songyun Zhu
Kyungsil Yoon
Peter F Johnson
Robert C Smart
North Carolina State University · USToxicologie, Pharmacologie et Signalisation Cellulaire · FRNational Cancer Institute · US

Funding

Role of CEBP transcription factors in regulating cell growth and tumorigenesisZIABC010328 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI JOHNSON, PETER F · 2009 to 2021
$17.5M
Role of CEBP transcription factors in regulating cell growth and tumorigenesisZ01BC010328 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI JOHNSON, PETER · 2000 to 2008
$3.0M
Role of C/EBPs in Squamous Differentiation and NeoplasiaR01CA046637 · NCI · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI SMART, ROBERT C · 1996 to 2011
$2.5M
Regulation and Function of C/EBP in UVB ResponsesR01ES012473 · NIEHS · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI SMART, ROBERT C · 2005 to 2010
$1.6M
DIACYLGLYCEROLS AS TUMOR PROMOTERSR29CA046637 · NCI · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI SMART, ROBERT C · 1990 to 1994
–
NCI NIH HHS CA 46637NCI NIH HHS R01 CA046637NIEHS NIH HHS ES 12473NIEHS NIH HHS R01 ES012473
6 · The paper itself

Abstract

CCAAT/enhancer binding protein alpha (C/EBPalpha) is a basic leucine zipper transcription factor that inhibits cell cycle progression and regulates differentiation in various cell types. C/EBPalpha is inactivated by mutation in acute myeloid leukemia (AML) and is considered a human tumor suppressor in AML. Although C/EBPalpha mutations have not been observed in malignancies other than AML, greatly diminished expression of C/EBPalpha occurs in numerous human epithelial cancers including lung, liver, endometrial, skin, and breast, suggesting a possible tumor suppressor function. However, direct evidence for C/EBPalpha as an epithelial tumor suppressor is lacking due to the absence of C/EBPalpha mutations in epithelial tumors and the lethal effect of C/EBPalpha deletion in mouse model systems. To examine the function of C/EBPalpha in epithelial tumor development, an epidermal-specific C/EBPalpha knockout mouse was generated. The epidermal-specific C/EBPalpha knockout mice survived and displayed no detectable abnormalities in epidermal keratinocyte proliferation, differentiation, or apoptosis, showing that C/EBPalpha is dispensable for normal epidermal homeostasis. In spite of this, the epidermal-specific C/EBPalpha knockout mice were highly susceptible to skin tumor development involving oncogenic Ras. These mice displayed decreased tumor latency and striking increases in tumor incidence, multiplicity, growth rate, and the rate of malignant progression. Mice hemizygous for C/EBPalpha displayed an intermediate-enhanced tumor phenotype. Our results suggest that decreased expression of C/EBPalpha contributes to deregulation of tumor cell proliferation. C/EBPalpha had been proposed to block cell cycle progression through inhibition of E2F activity. We observed that C/EBPalpha blocked Ras-induced and epidermal growth factor-induced E2F activity in keratinocytes and also blocked Ras-induced cell transformation and cell cycle progression. Our study shows that C/EBPalpha is dispensable for epidermal homeostasis and provides genetic evidence that C/EBPalpha is a suppressor of epithelial tumorigenesis.

Indexed as

Gene Expression Regulation, NeoplasticAnimalsApoptosisCCAAT-Enhancer-Binding Protein-alphaCell DifferentiationCell ProliferationEpidermisEpithelial CellsKeratinocytesMiceMice, Inbred BALB CMice, KnockoutMutationNIH 3T3 Cellsras ProteinsCCAAT-Enhancer-Binding Protein-alpharas Proteins

Identifiers

PMID17638888
PMCPMC3773581
OpenAlexW2126492930

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.